Health · 32 views
Ixekizumab + Tirzepatide boosts psoriatic arthritis outcomes more than Ixekizumab monotherapy
Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the American Academy…
Summary
Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Masked antibodies may open intracellular treatment route for Parkinson's diseaseContinue reading
- Third measles death recorded in US in 2026Continue reading
- Pancreatic tumors use clotting pathway to build immune shields, study findsContinue reading
- Pennsylvania reports apparent third measles-related death amid outbreakContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow